Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1606 to 1620 of 7712 results

  1. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)

    Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy.

  2. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA761)

    Evidence-based recommendations on osimertinib (Tagrisso) for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer in adults after complete tumour resection.

  3. Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies (TA786)

    Evidence-based recommendations on tucatinib (TUKYSA) for HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies.

  4. Ovarian cancer QS update

    In development [GID-QS10182] Expected publication date: 05 February 2025

  5. Alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension

    In development [GID-IPG10299] Expected publication date: 05 February 2025

  6. Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis

    In development [GID-IPG10392] Expected publication date: 05 February 2025

  7. Intravascular lithotripsy for calcified coronary arteries during percutaneous coronary intervention

    In development [GID-IPG10391] Expected publication date: 05 February 2025

  8. Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [ID6225]

    In development [GID-TA11263] Expected publication date: 05 February 2025

  9. Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]

    In development [GID-TA10784] Expected publication date: 05 February 2025

  10. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]

    In development [GID-TA11514] Expected publication date: 05 February 2025

  11. Masitinib with riluzole for treating amyotrophic lateral sclerosis TS ID 10728

    Awaiting development [GID-TA11071] Expected publication date: TBC

  12. AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images (DG55)

    Evidence-based recommendations on AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images

  13. Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (DG29)

    Evidence-based recommendations on multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis

  14. Tests in secondary care to identify people at high risk of ovarian cancer (DG31)

    Evidence-based recommendations on tests in secondary care to identify people at high risk of ovarian cancer. The tests are the IOTA ADNEX model, Overa (MIA2G)

  15. Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test) (DG39)

    Evidence-based recommendations on tests to help assess risk of acute kidney injury for people being considered for critical care admission. The tests are the